A single-molecule “molecular counter” turns prenatal testing into a high-margin cash engine while oncology liquid biopsy becomes the outsized call option—if reimbursement and patent risk don’t bite.
Overview
BillionToOne (BLLN) is a molecular diagnostics company commercializing a step-change in next-generation sequencing precision through Quantitative Counting Technology (QCT), effectively turning sequencing from a qualitative readout into a quantitative “molecular counter” capable of detecting extremely rare variants. Founded in 2016 by Stanford researchers and public as of Nov 6, 2025 (Nasdaq Global Select), the company monetizes QCT via per-test clinical diagnostics across two segments: prenatal screening (UNITY) and oncology liquid biopsy (Northstar). UNITY is differentiated by its maternal-only workflow for recessive-condition risk assessment, eliminating the paternal sample requirement that commonly disrupts standard care. Northstar applies the same counting architecture to therapy selection and treatment monitoring with reported detection limits down to 0.01% tumor fraction. Financially, 2025 marked an inflection: revenue doubled to $305.1M, test volume grew 51%, ASP increased materially (Q4 overall ASP $561), gross margins expanded to 71.4% in Q4, and the company reached GAAP operating profitability. With ~$496M in cash, broad reimbursement coverage (225M+ lives), and a large claimed ~$100B U.S. opportunity, the company is positioned to extend share gains in prenatal while scaling oncology as the major long-duration growth vector.